Purchase this article with an account.
V. Krochik, W. Loayza Gamboa, A. Saenz Valiente, F. Lerner; Quality of Life in Patients With Glaucoma in Buenos Aires, Argentina. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1585.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Different studies have addressed quality of life (QoL) in glaucoma. However, little has been published in terms of QoL in patients with glaucoma in Latin America. The purpose of this study was to evaluate the QoL in patients with mild, moderate, advanced, and very advanced glaucoma, using the 25-item National Eye Institute Visual Function Questionnaires (NEI-VFQ-25), in Buenos Aires, Argentina.
This was a prospective study. A Spanish version of the NEI-VFQ-25 was developed with a previously standardized method. Patients, 18 years or older, with diagnosis of glaucoma were enrolled. All participants completed a demographic and the NEI-VFQ-25 questionnaires and underwent a complete ophthalmic examination. Optic nerve glaucomatous damage in the best eye was used to divide the patients into 4 categories: mild, moderate, advanced, and very advanced glaucoma. Corresponding perimetric damage was also evaluated in reliable visual fields. Vision-specific health related-quality of life was measured using 2 subscales (general vision and distance activities) and the composite score of 10 subscales (general vision, visual pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, color vision and peripheral vision) of the NEI-VFQ-25. Subscale scores have a minimum value of 0 indicating extreme disability and a maximum score of 100 indicating no disability. NEI-VFQ-25 subscales scores were compared between all categories of glaucoma damage with the Anova and Kruskal Wallis test (post test analysis).
Eighty one patients completed the questionnaires, 59.2% were female (n= 48) and 80% were 50 years or older (n= 65). Compared with mild and moderate glaucoma, the very advanced glaucoma group had significantly lower NEI-VFQ-25 subscale scores for distance activities, general vision and composite score (p < .05). The very advanced glaucoma group had lower values for the composite score than the advanced glaucoma group (p < .05).
In our population, patients with very advanced glaucoma, had significantly lower NEI-VFQ-25 scores, when compared with the other groups. The NEI-VFQ-25 could be administered without difficulties in this population. Results of subscales may be used to address specific needs of these patients.
This PDF is available to Subscribers Only